News
OPK
1.640
-1.20%
-0.020
OPKO Health to Announce Q4 2024 Financial Results
TipRanks · 1d ago
Weekly Report: what happened at OPK last week (0203-0207)?
Weekly Report · 4d ago
Insiders continue to buy OPKO Health, Inc. (NASDAQ:OPK) and now own 52% shares
Simply Wall St · 02/06 10:05
Weekly Report: what happened at OPK last week (0127-0131)?
Weekly Report · 02/03 09:13
Insider trades: Verizon, Goldman Sachs among notable names this week
Seeking Alpha · 02/01 16:03
Weekly Report: what happened at OPK last week (0120-0124)?
Weekly Report · 01/27 09:13
Weekly Report: what happened at OPK last week (0113-0117)?
Weekly Report · 01/20 09:12
Opko, BioReference to pay over $700K to resolve False Claims Act allegations
TipRanks · 01/17 20:10
Opko Health Engages Investors at J.P. Morgan Conference
TipRanks · 01/15 22:48
OPKO Health, Inc.'s (NASDAQ:OPK) Share Price Could Signal Some Risk
Simply Wall St · 01/14 10:27
Weekly Report: what happened at OPK last week (0106-0110)?
Weekly Report · 01/13 09:12
Here's Why You Should Retain OPKO Health Stock in Your Portfolio
NASDAQ · 01/09 12:53
OPKO Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Barchart · 01/09 10:45
OPKO Health Announces Progress in EBV Vaccine Study, Stock Gains
NASDAQ · 01/08 14:11
OPKO Health Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 01/08 13:14
OPKO Health Price Target Maintained With a $3.00/Share by HC Wainwright & Co.
Dow Jones · 01/08 13:14
HC Wainwright & Co. Maintains Buy on OPKO Health, Maintains $3 Price Target
Benzinga · 01/08 13:04
Opko Health’s Promising Pipeline: Buy Rating Backed by Innovative Trials and Strategic Collaborations
TipRanks · 01/08 12:25
Opko Health subsidiary announces EBV vaccine enters Phase I study
TipRanks · 01/07 13:20
OPKO HEALTH’S MODEX THERAPEUTICS ANNOUNCES EPSTEIN-BARR VIRUS VACCINE CANDIDATE ENTERS PHASE I CLINICAL STUDY IN COLLABORATION WITH MERCK
Reuters · 01/07 13:00
More
Webull provides a variety of real-time OPK stock news. You can receive the latest news about Opko Health through multiple platforms. This information may help you make smarter investment decisions.
About OPK
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company focuses on leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. Its segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, Rayaldee product sales and its pharmaceutical research and development. The diagnostics segment primarily consists of point-of-care operations. Its pharmaceutical business features Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage three or four chronic kidney disease (CKD) and vitamin D insufficiency, and Somatrogon (hGH-CTP), a once-weekly human growth hormone injection. Its NGENLA (somatrogon-ghla), is a once-weekly, human growth hormone analog indicated for treatment of pediatric patients aged three years and older.